Cardiovascular outcomes in randomized trials: should time to first event for "hard" end points remain the standard approach?

J Am Coll Cardiol. 2009 Dec 15;54(25):2363-5. doi: 10.1016/j.jacc.2009.09.021.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Atorvastatin
  • Cardiovascular Diseases / drug therapy
  • Cardiovascular Diseases / mortality
  • Cardiovascular Diseases / prevention & control*
  • Cholesterol / blood
  • Endpoint Determination*
  • Heptanoic Acids / administration & dosage
  • Hospitalization
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
  • Myocardial Revascularization
  • Pravastatin / administration & dosage
  • Pyrroles / administration & dosage
  • Randomized Controlled Trials as Topic / methods*
  • Secondary Prevention
  • Stroke / prevention & control
  • Time Factors

Substances

  • Heptanoic Acids
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Pyrroles
  • Cholesterol
  • Atorvastatin
  • Pravastatin